BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2015 5:28:00 PM | Browse: 258 | Download: 256
Publication Name World Journal of Hepatology
Manuscript ID 14881
Country of Manuscript Source Italy
2014-10-29 08:44
Peer-Review Started
2014-11-01 11:42
To Make the First Decision
2014-12-12 17:27
Return for Revision
2014-12-16 13:16
2014-12-27 22:33
Second Decision
2015-01-21 20:58
Accepted by Journal Editor-in-Chief
2015-01-23 18:15
Accepted by Company Editor-in-Chief
2015-02-02 20:16
Articles in Press
2015-02-02 20:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-04-28 14:13
Publish the Manuscript Online
2015-05-19 17:28
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up
Manuscript Source Invited Manuscript
All Author List Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi and Andrea Lorenzo Inghilesi
Funding Agency and Grant Number
Funding Agency Grant Number
Protocollo TESORM by Regione Toscana
Università degli Studi di Firenze
Bayer Health Care s.p.a
Correspondence To Stefano Colagrande, MD, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Università degli Studi di Firenze-Azienda Ospedaliero-Universitaria Careggi, Radiodiagnostica 2, Largo Brambilla 3, 50134 Florence, Italy. stefano.colagrande@unifi.it
Keywords Modified Response Evaluation Criteria in Solid Tumors; Diffusion weighted imaging; Barcelona clinic liver cancer; Advanced hepatocellular carcinoma; Sorafenib; Advanced hepatocellular carcinoma second line therapies; Perfusion weighted imaging; Response evaluation; Hepatocellular carcinoma follow-up; Response Evaluation Criteria in Solid Tumors
Core Tip Advanced stage hepatocellular carcinoma comprehends a wide range of patients with different general conditions. The main therapeutic option is represented by sorafenib. Although the treatment has shown a significant increase in mean overall survival, only a part of patients actually shows benefits. Differentiating responder from non-responder patients is a pivotal challenge for the future. In particular, finding parameters quantitatively describing perfusion grade, and then able to predict the sensitivity of the lesions to anti-angiogenic agents could help stratifying patients in terms of responsiveness before the beginning of the therapy itself. This would bring a great help in management of these patients.
Publish Date 2015-05-19 17:28
Citation Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053
Url http://www.wjgnet.com/1948-5182/full/v7/i8/1041.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i8.1041
Full Article (PDF) WJH-7-1041.pdf
Full Article (Word) WJH-7-1041.doc
Revised Manuscript 14881-Review.docx
Peer-review Report 14881-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 14881-Journal Editor-in-Chief's Review Report.pdf
Answering Reviewers 14881-Answering reviewers.pdf
Scientific Misconduct Check 14881-CrossCheck.jpg
Scientific Editor Work List 14881-Scientific editor work list.pdf
Conflict-of-Interest Disclosure Form 14881-Conflict-of-interest statement.pdf
Copyright License Agreement 14881-Copyright assignment.pdf